Home / Publication / Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110

刊物

Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110

Author(s): Diana Clarke, Mark Mirochnick, Edward Acosta, Edmund Capparelli, Anne Chain, Hedy Teppler, Betsy Smith, Jos Lommerse

Year: 2019 年 12 月 1 日

Blending Science & Impact in Drug Development: Felix Boakye-Agyeman, Vice President of the QSS Division at Certara

视频

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110

Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110

Enabling Personalized Therapy with PBPK Modeling for Pediatric Epilepsy

Calculating AUC (Linear and Log-linear)

Accumulation: What It Means and How to Calculate It

Blending Science & Impact in Drug Development: Felix Boakye-Agyeman, Vice President of the QSS Division at Certara

订阅时事通讯

快捷链接

解决方案

联系我们